Dr. Willmott on Expanding Genomic Testing in Ovarian Cancer

Video

Lyndsay Willmott, MD, discusses the expanding role for genomic testing in ovarian cancer.

Lyndsay Willmott, MD, gynecologic oncologist, Arizona Oncology, discusses the expanding role for genomic testing in ovarian cancer.
Companion diagnostics are available to identify patients with homologous recombination deficiency (HRD)–positive ovarian cancer, Willmott says. However, not all patients within this subgroup are being captured with current testing options. As such, genomic testing will continue to evolve to better identify the genomic scarring associated with this disease subtype, Willmott explains. 

Additionally, genomic assays are available to identify germline mutations that span several different genes, Willmott adds.

Most clinicians utilize HRD testing routinely, as it captures the largest pool of patients with ovarian cancer, Willmott continues. Additionally, reflex testing can determine whether HRD positivity is related to an underlying germline mutation, Willmott says. Finally, germline mutations are important to uncover so that a patient’s family members can be tested if indicated, Willmott concludes.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD